MedPath

Acetic Acid 2% Solution for Skin Ulcers

Phase 3
Not yet recruiting
Conditions
Ulcer, Skin
Interventions
Drug: Prontosan
Drug: Acetic Acid
Registration Number
NCT06297967
Lead Sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Brief Summary

The objective of this clinical trial is to assess the effectiveness of acetic acid in patients suffering from chronic cutaneous ulcers with biofilm. The primary question it seeks to address is whether acetic acid (as a 2% topical solution) is superior to the current standard treatment for chronic cutaneous ulcers with biofilm at our center (Prontosan®).

Participants will be randomly assigned to receive either the acetic acid solution treatment or the standard current treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
104
Inclusion Criteria
  • Patients over 18 years of age.
  • Continued care (hospital or outpatient) in one of the Consorci Sanitari Alt Penedes i Garraf (CSAPG) units.
  • Presence of a cutaneous ulcer with biofilm, with an area of less than 120 cm2, and in any location (except the facial region).
  • Plan to undergo treatment and follow-up of the lesion (at least 8 weeks) at the study center.
  • Ability to cooperate in necessary evaluations.
  • Informed consent for inclusion in the study, either from the participant themselves or from their legal representative.
Read More
Exclusion Criteria
  • Participants diagnosed with any of the following conditions:

    1. Ulcers with exposed bone tissue.
    2. Neoplastic-origin ulcers.
    3. Ulcers lasting more than 18 months.
  • Participation in another clinical trial involving an experimental intervention during the period of the current trial and/or establishing a visit frequency incompatible with the current trial.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupProntosanTopic application of Prontosan® for 15 min, typically administered every 24h. The frequency of the treatments may be modified according to the evolution of the lesion at the discretion of the nurse in charge of the treatments
Acetic AcidAcetic AcidTopic application of a Acetic Acid 2% solution for 15 min, typically administered every 24h. The frequency of the treatments may be modified according to the evolution of the lesion at the discretion of the nurse in charge of the treatments
Primary Outcome Measures
NameTimeMethod
Change in ulcer area compared to baseline (percentage) at 8 weeks of treatment8 weeks

The assessment of the ulcer will include measuring its area through digital planimetry.

Secondary Outcome Measures
NameTimeMethod
Percentage of participants with ulcer healing at 12 weeks from the start of treatment.12 weeks

The assessment of the ulcer will performed by the nurse responsible for monitoring the ulcer. The ulcer will be considered fully healed when the surface is epithelialized.

Number of adverse reactions associated with the treatment, collected from the medical record.12 weeks

The number of adverse reactions will be evaluated through the review of the participant's medical records by a trained member of the research team.

Percentage of participants with ulcer healing at 4 weeks from the start of treatment.4 weeks

The assessment of the ulcer will performed by the nurse responsible for monitoring the ulcer. The ulcer will be considered fully healed when the surface is epithelialized.

Time (days) to ulcer healing from the start of treatment.up to 12 weeks

The lesion will be considered fully healed when the surface is epithelialized. This will be confirmed by the nurse responsible for monitoring the lesion.

Changes in the wound bed at 8 weeks according to score of section 6 of the RESVECH2.0 ("Expected Results of the Assessment and Evaluation of Healing of Chronic Wounds" scale.8 weeks

The evaluation of changes will be conducted by a trained nurse to apply the RESVECH 2.0 scale. The scores in Section 6 of the RESVECH scale range from 0 to 14. The higher the score, the greater the severity of the injury.

The healthcare expenditure associated with each branch of the study12 weeks

A descriptive analysis of healthcare expenditure associated with each study branch will be conducted using billing data from the center, which is linked to the insured individual's resource utilization.

Change in ulcer area compared to baseline (percentage) at 4 weeks of treatment4 weeks

The assessment of the ulcer will include measuring its area through digital planimetry.

Change in ulcer area compared to baseline (percentage) at 12 weeks of treatment12 weeks

The assessment of the ulcer will include measuring its area through digital planimetry.

Trial Locations

Locations (1)

Consorci Sanitari Alt'Pènedes i Garraf

🇪🇸

Barcelona, Cataluña, Spain

© Copyright 2025. All Rights Reserved by MedPath